These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 28748653

  • 1. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Lewis DJ, Huang S, Duvic M.
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
    [Abstract] [Full Text] [Related]

  • 2. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, Kulikowski W, Prejzner W, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Rogowski W, Grzanka A, Placek W, Lugowska-Umer H, Kowalczyk A, Nowicki R, Jurczak W.
    Am J Ther; 2016 Sep; 23(3):e749-56. PubMed ID: 24732904
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Sep; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
    Mehlmauer MA.
    Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
    [Abstract] [Full Text] [Related]

  • 7. Long-term control of mycosis fungoides of the hands with topical bexarotene.
    Lain T, Talpur R, Duvic M.
    Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
    [Abstract] [Full Text] [Related]

  • 8. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M.
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [Abstract] [Full Text] [Related]

  • 9. Follicular mycosis fungoides: successful treatment with oral bexarotene.
    Shistik G, Scalf LA, Fenske N, Glass LF.
    J Drugs Dermatol; 2004 Nov; 3(3):301-4. PubMed ID: 15176165
    [Abstract] [Full Text] [Related]

  • 10. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC.
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M.
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [Abstract] [Full Text] [Related]

  • 12. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
    Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM.
    Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
    [Abstract] [Full Text] [Related]

  • 13. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 14. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ.
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [Abstract] [Full Text] [Related]

  • 15. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy.
    Huber MA, Kunzi-Rapp K, Staib G, Scharffetter-Kochanek K.
    J Am Acad Dermatol; 2004 Mar; 50(3):475-6. PubMed ID: 14988696
    [No Abstract] [Full Text] [Related]

  • 16. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M, García-Arpa M, González-García J.
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [Abstract] [Full Text] [Related]

  • 17. Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
    Wong SF.
    Ann Pharmacother; 2001 Sep; 35(9):1056-65. PubMed ID: 11573857
    [Abstract] [Full Text] [Related]

  • 18. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 19. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
    Calzavara-Pinton P, Leali C, Venturini M, Sala R, Zane C.
    Eur J Dermatol; 2007 May; 17(4):341-2. PubMed ID: 17540649
    [No Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
    Hamada T, Tokura Y, Sugaya M, Ohtsuka M, Tsuboi R, Nagatani T, Kiyohara E, Tani M, Setoyama M, Matsushita S, Kawai K, Yonekura K, Saida T, Iwatsuki K.
    J Dermatol; 2019 Jul; 46(7):557-563. PubMed ID: 31090237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.